Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,291 active trials259 approved drugs3,814 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,377 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04870034 | Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer | withdrawn | Early Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT05980507 | An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201 Infusion in Relapsed/Refractory Multiple Myeloma | withdrawn | Phase 1 | 0 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Dec 22, 2023 |
| clinicaltrials |
| NCT05465590 | A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer | withdrawn | Early Phase 1 | 0 | Mainline Biosciences, Inc.INDUSTRY | 0 | Dec 21, 2023 | clinicaltrials |
| NCT02531854 | A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy | withdrawn | Phase 2 | 0 | Advaxis, Inc.INDUSTRY | 0 | Dec 19, 2023 | clinicaltrials |
| NCT04151563 | A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy(CheckMate 79X) | withdrawn | Phase 1 / Phase 2 | 0 | Bristol-Myers SquibbINDUSTRY | 10 | Dec 19, 2023 | clinicaltrials |
| NCT00250016 | Pharmacology Study of Aerosolized Liposomal 9-Nitro-20 (S)-Camptothecin (L9NC) | withdrawn | — | 0 | University of New MexicoOTHER | 1 | Dec 14, 2023 | clinicaltrials |
| NCT05948462 | Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib(NSCLC) | withdrawn | Phase 2 | 0 | SCRI Development Innovations, LLCOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT03338712 | Micro-RNA Expression Profiles in Localised Prostate Cancer | withdrawn | — | 0 | Wuerzburg University HospitalOTHER | 0 | Dec 12, 2023 | clinicaltrials |
| NCT00548730 | Comparison Trial of White Light, Autofluorescence and Narrow Band Imaging Bronchoscopy(NWA) | withdrawn | — | 0 | Antonios LikourezosOTHER | 1 | Dec 11, 2023 | clinicaltrials |
| NCT05201183 | A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Naoyuki G. Saito, M.D., Ph.D.OTHER | 1 | Dec 11, 2023 | clinicaltrials |
| NCT05702385 | Clinical Utility Study for Exo-PDAC | withdrawn | N/A | 0 | Qure Healthcare, LLCINDUSTRY | 1 | Dec 7, 2023 | clinicaltrials |
| NCT06159998 | New Markers for Treatment Response to Radiotherapy in Prostate Cancer | withdrawn | — | 0 | University of BaselOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT02017366 | Design of the EFECTS Trial(EFECTS) | withdrawn | N/A | 0 | University Hospital, GasthuisbergOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT04361058 | Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide | withdrawn | Phase 1 | 0 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT02519140 | Assessing How the Viscosity of Submucosal Gel Injections Helps With Endoscopic Mucosal Resections | withdrawn | Phase 3 | 0 | Antonios LikourezosOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT05321940 | Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias | withdrawn | Phase 1 | 0 | Juan C. Ramos, MDOTHER | 0 | Dec 4, 2023 | clinicaltrials |
| NCT04892875 | A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers(PANTHEoN) | withdrawn | Phase 1 | 0 | Jennifer ChoeOTHER | 0 | Nov 30, 2023 | clinicaltrials |
| NCT00657332 | Clinical and Pathologic Studies in Neuroendocrine Tumors | withdrawn | — | 0 | Stanford UniversityOTHER | 0 | Nov 28, 2023 | clinicaltrials |
| NCT05641922 | Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of Liver Tissue Ablation Procedures (PANORAMA2)(PANORAMA2) | withdrawn | N/A | 0 | Techsomed Medical Technologies LTDINDUSTRY | 0 | Nov 27, 2023 | clinicaltrials |
| NCT04629209 | A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma | withdrawn | Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT04835987 | Evaluation of the Autonomic Nervous System in Patients Undergoing Esophagectomy for Cancer(PROSNACO) | withdrawn | — | 0 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT05259813 | Phase I Study of JWCAR029 in Subjects With R/R CLL/SLL | withdrawn | Phase 1 | 0 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT03735589 | Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05998941 | A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer | withdrawn | Phase 2 | 0 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Nov 22, 2023 | clinicaltrials |
| NCT04555603 | Axitinib Therapy Management Study | withdrawn | — | 0 | PfizerINDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
| NCT04864522 | Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma(MM FPBMC) | withdrawn | Phase 1 / Phase 2 | 0 | University of VirginiaOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT02143050 | Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients | withdrawn | Phase 1 / Phase 2 | 0 | University of LouisvilleOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT02432417 | The Addition of Chloroquine to Chemoradiation for Glioblastoma, | withdrawn | Phase 2 | 0 | Maastricht Radiation OncologyOTHER | 0 | Nov 18, 2023 | clinicaltrials |
| NCT04602117 | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer | withdrawn | Phase 1 | 0 | QuantumLeap Healthcare CollaborativeOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT05647512 | Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases | withdrawn | Phase 1 / Phase 2 | 0 | LaNova Medicines LimitedINDUSTRY | 0 | Nov 18, 2023 | clinicaltrials |
| NCT05321862 | Relevance Evaluation of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal Residual Disease in Multiple Myeloma Patients.(PENTI-MIDAS) | withdrawn | Phase 2 | 0 | Nantes University HospitalOTHER | 1 | Nov 15, 2023 | clinicaltrials |
| NCT02232646 | A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies | withdrawn | Phase 2 | 0 | Sumitomo Pharma America, Inc.INDUSTRY | 0 | Nov 14, 2023 | clinicaltrials |
| NCT05454371 | Investigation of Urinary Biomarkers for the Detection of Prostate Cancer(URODETECT-WP2) | withdrawn | N/A | 0 | Novosanis NVINDUSTRY | 1 | Nov 13, 2023 | clinicaltrials |
| NCT05929716 | An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Nov 13, 2023 | clinicaltrials |
| NCT06050954 | A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)(CARMA) | withdrawn | Phase 2 | 0 | Fox Chase Cancer CenterOTHER | 0 | Nov 9, 2023 | clinicaltrials |
| NCT05111314 | Comparison of Hepatic Intraarterial Versus Systemic Intravenous 68Ga-PSMA PET/CT for Detection of Hepatocellular Carcinoma | withdrawn | Early Phase 1 | 0 | Mayo ClinicOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT05301595 | TAP vs QL for Postoperative Analgesia After DIEP Free Flap Breast Reconstruction | withdrawn | N/A | 0 | Ottawa Hospital Research InstituteOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT05712941 | Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer | withdrawn | Phase 3 | 0 | EQRx International, Inc.INDUSTRY | 0 | Nov 3, 2023 | clinicaltrials |
| NCT04054752 | Vaccine Response With NT-I7 | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Nov 2, 2023 | clinicaltrials |
| NCT05943314 | Clinical Study on Safety and Efficacy of Anti-CLL1 /+CD33 CAR T Cells in the Treatment of Acute Myeloid Leukemia | withdrawn | N/A | 0 | Guangzhou Bio-gene Technology Co., LtdINDUSTRY | 1 | Nov 2, 2023 | clinicaltrials |
| NCT04684979 | Transplantation of Hematopoietic Stem Cells From HLA-compatible Donors in Patients With B-Cell Lymphoid Malignancies | withdrawn | Phase 2 | 0 | Baptist Health South FloridaOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT05222438 | Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant | withdrawn | Phase 2 | 0 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT05120622 | Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer(Rideau) | withdrawn | Phase 1 / Phase 2 | 0 | University of British ColumbiaOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT05073809 | Photoacoustic Imaging of Head and Neck Tumours | withdrawn | — | 0 | University College, LondonOTHER | 0 | Oct 27, 2023 | clinicaltrials |
| NCT06017323 | Proglumide With Gemcitabine and Nab-Paclitaxel in PatientsWith Metastatic Pancreatic Ductal Adenocarcinoma(ProglumidePanc) | withdrawn | Phase 1 | 0 | Georgetown UniversityOTHER | 1 | Oct 25, 2023 | clinicaltrials |
| NCT00180739 | Safety Trial of Magnetic Resonance (MR) Guided Focused Ultrasound Surgery (FUS) in Women With Uterine Fibroids Wishing to Pursue Pregnancy in the Future | withdrawn | Phase 4 | 0 | Imperial College LondonOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT03341364 | Acceptance and Commitment Based Group Therapy for Cancer Patients | withdrawn | N/A | 0 | Region SkaneOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT05737849 | A Study to Learn About the Tests Looking for a Gene Mutation in Adults With Lung Cancer in China (ELEGANT)(ELEGANT) | withdrawn | — | 0 | TakedaINDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT04648189 | Cetuxibab to Reduce Circulating Tumor Cells in Early Stage NSCLC | withdrawn | Phase 2 | 0 | The Netherlands Cancer InstituteOTHER | 1 | Oct 19, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Dec 22, 2023source: clinicaltrials